World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

Cision PR Newswire by Cision PR Newswire
June 18, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter
  • Strong recruitment momentum demonstrated in 2026
  • Year-to-date recruitment has already surpassed total enrollment for 2025

OSLO, Norway, June 18, 2026 /PRNewswire/ — Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone.

A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the highest recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025.

Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment.

“Reaching the halfway point for recruitment in our Phase 2 trial is an important milestone for Oncoinvent and reflects the strong commitment of investigators and study sites,” said Oystein Soug, CEO of Oncoinvent. “We are pleased to see the steps taken to accelerate recruitment translating into the strong enrollment momentum seen in 2026. Building on the encouraging safety profile and preliminary efficacy signals observed in earlier studies, we look forward to further evaluating Radspherin’s potential to improve outcomes for patients with peritoneal metastases from ovarian cancer, who have limited treatment options following surgery.”

The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin® in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin® following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone.

Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin® is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com

Optimum Strategic Communications
Zoe Bolt, Elena Bates, Katherine Bliss
+44 (0) 203 882 9621
oncoinvent@optimumcomms.com

This information was brought to you by Cision https://news.cision.com

https://news.cision.com/oncoinvent-asa/r/oncoinvent-achieves-50–recruitment-milestone-in-phase-2-ovarian-cancer-study-of-radspherin-,c4365060

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/oncoinvent-achieves-50-recruitment-milestone-in-phase-2-ovarian-cancer-study-of-radspherin-302803997.html

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • LEN Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Against Lennar Corporation

    0 shares
    Share 0 Tweet 0
  • Wipfli recognized in the FY26 Sage Platinum Club for Partners Awards for New Client Acquisition Annual Recurring Revenue Year-over-Year Growth

    0 shares
    Share 0 Tweet 0
  • Global Times: China’s role as APEC’s rotating chair creates an opportunity for all parties to build common ground: director of ABAC Secretariat

    0 shares
    Share 0 Tweet 0
  • AI is Boosting Productivity Gains as Asset and Wealth Managers Balance Client Priorities with Execution and Growth, Annual MMI-Broadridge Survey Reveals

    0 shares
    Share 0 Tweet 0
  • Waterfall Asset Management Provides $48 Million Senior Loan to Refinance Portofino Inn & Suites Anaheim

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler